Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGILE COVID-19 treatment platform study
ISRCTN27106947Phase 2Recruiting
- Sponsor
- University of Liverpool
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
A Phase 2 trial of ALG-097558, remdesivir, molnupiravir, nitazoxanide, sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by University of Liverpool. Started Mar 2020; status: recruiting.
02
Drugs
ALG-097558remdesivirmolnupiravirnitazoxanidesotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN27106947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN27106947.